Q2 2026 13F · SEC CIK 1595725

Rock Springs Capital Management LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $2.0B
Reported positions: 104
Top holdings a year, 3 yrs: +14.9%
Assets under management: $2.4B

Rock Springs Capital Management LP is a hedge fund that reported 104 positions worth $2.0B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Revolution Medicines Inc (RVMD, 10.1%), Travere Therapeutics Inc (TVTX, 6.0%), Eli Lilly & Co (LLY, 5.8%). A portfolio copying its top holdings returned 14.9% a year over the last 3 years, against 20.4% for the S&P 500.

Rock Springs Capital Management LP holdings largest 50 of 104 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Rock Springs Capital Management LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
RVMDRevolution Medicines Inc	10.1%	6.9%	1,105,210	-8.6%	$207.0M
TVTXTravere Therapeutics Inc	6.0%	2.6%	2,179,069	+47.4%	$123.8M
LLYEli Lilly & Co	5.8%	5.4%	98,700	+0.0%	$118.4M
MDGLMadrigal Pharmaceuticals Inc	4.6%	5.3%	174,999	+2.3%	$94.0M
MIRMMirum Pharmaceuticals Inc	4.6%	4.4%	798,145	-1.6%	$93.4M
RYTMRhythm Pharmaceuticals Inc	3.8%	3.5%	692,598	+0.4%	$76.9M
KYMRKymera Therapeutics Inc	2.5%	2.4%	453,156	-8.8%	$52.0M
ARGNFArgenx SE	2.4%	4.2%	52,750	-46.4%	$48.9M
ASNDAscendis Pharma A/s	2.2%	—	168,750	—	$45.0M
XENEXenon Pharmaceuticals Inc	2.0%	2.6%	683,907	-10.4%	$41.3M
SRRKScholar Rock Hldg Corp	1.9%	2.1%	715,452	-3.3%	$39.3M
INSMInsmed Inc	1.9%	3.0%	362,150	+15.2%	$38.6M
PENPenumbra, Inc.	1.8%	2.3%	115,750	-3.9%	$36.5M
GPCRStructure Therapeutics F Unspo	1.7%	1.8%	640,317	+0.0%	$34.4M
RAREUltragenyx Pharmaceutical in	1.6%	1.5%	967,855	-20.6%	$32.3M
IRTCIrhythm Technologies Inc	1.6%	1.8%	269,650	+3.0%	$32.1M
ISRGIntuitive Surgical Inc	1.5%	2.2%	76,460	-6.8%	$30.4M
AGLAgilon Health Inc	1.4%	—	262,600	—	$28.1M
UNHUnitedhealth Group Inc	1.3%	0.8%	63,750	+20.3%	$26.5M
CLDXCelldex Therapeutics Inc New	1.3%	1.2%	699,146	+7.5%	$26.0M
ERASErasca, Inc.	1.3%	1.1%	1,402,150	+27.1%	$25.7M
NBIXNeurocrine Biosciences Inc	1.2%	1.2%	144,750	-3.8%	$24.4M
ELVNEnliven Therapeutics Inc	1.2%	1.9%	464,625	-43.8%	$23.6M
THCTenet Healthcare Corp	1.1%	1.4%	125,000	+0.0%	$23.4M
DXCMDexcom Inc	1.1%	1.3%	343,000	-3.5%	$23.1M
ACRSAclaris Therapeutics Inc	1.1%	1.0%	4,330,532	-3.2%	$22.9M
MMEDMinimed Group Inc	1.1%	0.9%	1,520,000	+44.1%	$22.7M
BSXBoston Scientific Corp	1.1%	1.9%	528,500	+2.6%	$22.6M
PHVSPharvaris N V	1.1%	1.1%	648,333	+0.4%	$22.4M
AVLNAvalyn Pharmaceuticals Inc	1.1%	—	662,918	—	$21.8M
COAGHemab Therapeutics Holdings Inc	1.0%	—	575,432	—	$21.1M
DYNDyne Therapeutics Inc	1.0%	1.0%	942,154	-3.1%	$20.9M
ALNYAlnylam Pharmaceuticals Inc	1.0%	1.4%	66,750	-9.8%	$20.1M
COGTCogent Biosciences Inc	1.0%	1.4%	515,917	-17.3%	$20.0M
AGIOAgios Pharmaceuticals Inc	1.0%	1.6%	532,563	-33.4%	$19.8M
NAMSNewamsterdam Pharma Company Ordinary	1.0%	1.1%	582,744	-1.0%	$19.7M
VERAVera Therapeutics Inc Class A	0.9%	1.2%	427,584	-15.1%	$18.3M
TARSTarsus Pharmaceuticals Inc	0.9%	0.9%	277,087	+23.1%	$17.4M
HTFLHeartflow Inc	0.8%	0.8%	573,500	+0.2%	$16.8M
MBXMbx Biosciences Inc	0.8%	—	298,218	—	$16.5M
CYTKCytokinetics	0.8%	—	187,980	—	$16.0M
BCAXBicara Therapeutics Inc	0.8%	0.6%	535,286	+9.4%	$15.9M
PBLSParabilis Medicines, Inc.	0.8%	—	578,028	—	$15.8M
ZLABZai Lab Ltd	0.8%	0.9%	814,707	+0.0%	$15.5M
DHRDanaher Corp Del	0.7%	0.7%	76,300	+24.1%	$14.5M
TNGXTango Therapeutics Inc	0.7%	—	456,551	—	$14.3M
EVHEvolent Health Inc	0.7%	—	2,500,000	—	$13.6M
PTCTPtc Therapeutics Inc	0.6%	0.7%	162,298	+0.3%	$13.2M
MLYSMineralys Therapeutics Inc	0.6%	0.7%	484,951	+10.3%	$13.1M
ZBIOZenas Biopharma Inc	0.6%	0.6%	502,077	+0.0%	$12.7M

What Rock Springs Capital Management LP bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +49.9% /yr; S&P 500 +20.1%
3 years: +14.9% /yr; S&P 500 +20.4%
5 years: +2.8% /yr; S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$2.0B	104
Q1 2026	$1.7B	100
Q4 2025	$1.9B	97
Q3 2025	$1.7B	91
Q2 2025	$1.6B	92
Q1 2025	$1.7B	95
Q4 2024	$2.6B	105
Q3 2024	$3.1B	107
Q2 2024	$3.3B	107
Q1 2024	$3.9B	109
Q4 2023	$4.0B	99
Q3 2023	$3.7B	116

Questions about Rock Springs Capital Management LP's portfolio

What stocks does Rock Springs Capital Management LP own?

Rock Springs Capital Management LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 104 positions worth $2.0B. The largest are Revolution Medicines Inc (RVMD) at 10.1%, Travere Therapeutics Inc (TVTX) at 6.0%, Eli Lilly & Co (LLY) at 5.8%, Madrigal Pharmaceuticals Inc (MDGL) at 4.6% and Mirum Pharmaceuticals Inc (MIRM) at 4.6%.

What did Rock Springs Capital Management LP buy last quarter?

In Q2 2026, Rock Springs Capital Management LP added Travere Therapeutics Inc (TVTX) (+47.4% shares), Minimed Group Inc (MMED) (+44.1% shares) and Erasca, Inc. (ERAS) (+27.1% shares), compared with its Q1 2026 filing.

What did Rock Springs Capital Management LP sell last quarter?

In Q2 2026, Rock Springs Capital Management LP cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Arcellx Inc (ACLX), cut from its top 50 Compass Therapeutics Inc (CMPX), cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Ardelyx Inc (ARDX), Argenx SE (ARGNF) (-46.4% shares), Enliven Therapeutics Inc (ELVN) (-43.8% shares) and Agios Pharmaceuticals Inc (AGIO) (-33.4% shares), compared with its Q1 2026 filing.

How has Rock Springs Capital Management LP's portfolio performed?

A portfolio copying Rock Springs Capital Management LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +14.9% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +49.9% against +20.1%. Over 5 years: +2.8% a year against +11.6%.

When is Rock Springs Capital Management LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Rock Springs Capital Management LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Rock Springs Capital Management LP manage?

Rock Springs Capital Management LP reported $2.4B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $2.0B.